Effects of risedronate on the morphology and viability of gingiva-derived mesenchymal stem cells

Kim,Bo‑Bae; Ko,Youngkyung; Park,Jun‑Beom

doi:10.3892/br.2015.520

Effects of risedronate on the morphology and viability of gingiva-derived mesenchymal stem cells

Authors:
- Bo‑Bae Kim
- Youngkyung Ko
- Jun‑Beom Park
View Affiliations

Affiliations: Department of Periodontics, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
Published online on: September 28, 2015 https://doi.org/10.3892/br.2015.520
Pages: 845-848

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Risedronate has been used for the prevention and treatment of postmenopausal and corticosteroid-induced osteoporosis. The present study was performed to evaluate the effects of risedronate on the morphology and viability of human stem cells derived from the gingiva. Stem cells derived from the gingiva were grown in the presence of risedronate at concentrations that ranged from 1 to 10 µM. The morphology of the cells was viewed under an inverted microscope, and cell proliferation was analyzed with a cell counting kit‑8 (CCK‑8) on days 2, 4 and 7. The untreated control group showed a spindle‑shaped, fibroblast‑like morphology. The shapes of the cells treated with 1 and 5 µM risedronate were similar to that of the control group on day 2. However, morphology of the 10 µM group markedly differed from that of the control group. The shapes of the cells in the 1, 5 and 10 µM groups were rounder, and pronounced alterations when compared with the untreated control group were noted in all groups on day 7. The cultures growing in the presence of risedronate showed decreased CCK‑8 values on day 7. In conclusion, risedronate produced notable alterations in the morphology of the cells and reduced the viability of gingival mesenchymal stem cells.

View Figures

View References

1	Casado-Díaz A, Santiago-Mora R, Dorado G and Quesada-Gómez JM: Risedronate positively affects osteogenic differentiation of human mesenchymal stromal cells. Arch Med Res. 44:325–334. 2013. View Article : Google Scholar : PubMed/NCBI
2	Crandall C: Risedronate: A clinical review. Arch Intern Med. 161:353–360. 2001. View Article : Google Scholar : PubMed/NCBI
3	Dunn CJ and Goa KL: Risedronate. A review of its pharmacological properties and clinical use in resorptive bone disease. Drugs. 61:685–712. 2001. View Article : Google Scholar : PubMed/NCBI
4	Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M and Snorre Øfjord E: Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: A multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther. 29:1937–1949. 2007. View Article : Google Scholar : PubMed/NCBI
5	D'Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona GP and Isaia G: Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res. 23:373–379. 2008. View Article : Google Scholar : PubMed/NCBI
6	Jin SH, Lee JE, Yun JH, Kim I, Ko Y and Park JB: Isolation and characterization of human mesenchymal stem cells from gingival connective tissue. J Periodontal Res. 50:461–467. 2015. View Article : Google Scholar : PubMed/NCBI
7	Fujita H, Kurokawa K, Ogino T, Ono M, Yamamoto M, Oka T, Nakanishi T, Kobayashi N, Tanaka N, Ogawa T, et al: Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells. Basic Clin Pharmacol Toxicol. 109:78–84. 2011. View Article : Google Scholar : PubMed/NCBI
8	White NJ and Perry CM: Risedronate once a week. Treat Endocrinol. 2:415–420; discussion 421. 2003. View Article : Google Scholar : PubMed/NCBI
9	Frampton JE: Risedronate on two consecutive days per month. Drugs Aging. 26:355–362. 2009. View Article : Google Scholar : PubMed/NCBI
10	Dougherty JA: Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis. Ann Pharmacother. 36:512–516. 2002. View Article : Google Scholar : PubMed/NCBI
11	Tauchmanovà L, De Simone G, Musella T, Orio F, Ricci P, Nappi C, Lombardi G, Colao A, Rotoli B and Selleri C: Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant. 37:81–88. 2006.PubMed/NCBI
12	Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R, Zanchetta J, Olszynski WP, Recker RR and McClung MR: Monthly dosing of 75 mg risedronate on 2 consecutive days a month: Efficacy and safety results. Osteoporos Int. 19:1039–1045. 2008. View Article : Google Scholar : PubMed/NCBI
13	Ogura Y, Gonsho A, Cyong JC and Orimo H: Clinical trial of risedronate in Japanese volunteers: A study on the effects of timing of dosing on absorption. J Bone Miner Metab. 22:120–126. 2004. View Article : Google Scholar : PubMed/NCBI
14	Mitchell DY, Barr WH, Eusebio RA, Stevens KA, Duke FP, Russell DA, Nesbitt JD, Powell JH and Thompson GA: Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res. 18:166–170. 2001. View Article : Google Scholar : PubMed/NCBI
15	Peris P, Atkinson EJ, Gössl M, Kane TL, McCready LK, Lerman A, Khosla S and McGregor UI: Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women. Mayo Clin Proc. 88:46–55. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wang G, Zhu Z, Lei C, Li M, Liu F, Mao Y, Yu Z, Liu M, Zhao X and Tang T: Low-dose risedronate sodium protects bone cells after abrupt oestrogen withdrawal. J Int Med Res. 40:1761–1774. 2012. View Article : Google Scholar : PubMed/NCBI
17	Park JB, Zhang H, Lin CY, Chung CP, Byun Y, Park YS and Yang VC: Simvastatin maintains osteoblastic viability while promoting differentiation by partially regulating the expressions of estrogen receptors α. J Surg Res. 174:278–283. 2012. View Article : Google Scholar : PubMed/NCBI